

Sandoz to speak on their first biosimilar approved by the FDA at Biosimilars & Biobetters USA in Iselin

SMi reports(2015.06.24, Iselin) John Pakulski, Head US Biopharmaceutical Regulatory Affairs Sandoz, will be presenting at Biosimilars & Biobetters USA in Iselin

ISELIN, NEW JERSEY, UNITED STATES OF AMERICA, June 24, 2015 /EINPresswire.com/ -- The US biosimilars market is expected to reach \$2 billion by 2018* and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. SMi's conference on [Biosimilars & Biobetters USA](http://www.biosimilars-usa.com/evvnt) 2015 will offer effective strategies and solutions for developing cost effective biosimilars for the future, through a series of exciting discussions, presentations and workshops, delivered by true biosimilar leaders and industry pioneers.



Event Highlight: John Pakulski, Head US Biopharmaceutical Regulatory Affairs, Sandoz, will be giving a [spotlight presentation](#) on Day 1 of the conference on "The first biosimilar approved by FDA".

Download the [event programme](#) at <http://www.biosimilars-usa.com/einnews>

BENEFITS OF ATTENDING BIOSIMILARS & BIOBETTERS USA 2015:

- Evaluating the regulatory landscape and pharmacovigilance of biosimilars
- Assessing and challenging the BPCIA's dispute resolution process
- Understanding and recognising the technical challenges in biosimilars
- Discussing how to strategically plan and revolutionise biologics manufacturing
- Reviewing the status on biosimilars - Clinical development and continued progress
- Recognising commercialisation strategies & improving market development
- Developing further awareness on biobetters; are they the future?
- Examining unexpected in results in Immunogenicity testing

Featured Speakers of Biosimilars USA 2015:

- Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety
- Carsten Brockmeyer, CEO, Formycon AG

- Chetak Buaria, Director, Alliance Manager, Merck Serono International S.A.
- Cliff Mintz, Senior Writer/Correspondent, Life Science Leader
- Dominic Adair, Partner, Patent Litigation, Bristows
- Jim Nelson, Senior Principal and Owner, Adversarial Proceedings/Pharma & Biotech, Schwegman Lundberg Woessner & Kluth
- John Pakulski, Senior Director and Head US Biopharmaceutical Regulatory Affairs, Sandoz Inc.
- Magdalena Leszczyniecka, Founder and CEO, STC Biologics Inc
- Michael Kleinrock, Research, Director, IMS Health Inc
- Michael Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan
- Raju Shantha, Scientific Director, Biologics Research, Janssen Pharmaceuticals, Inc.
- Ravi S. Harapanhalli, Vice President and Former FDA Senior Executive, Parexel International
- Richard Diccio, Chairman, Harvest Moon Pharmaceuticals
- Robin Chadwick, Principal, Biotechnology, Schwegman Lundberg Woessner & Kluth
- Sean Xue, Director Portfolio Management, Dr Reddy's Laboratories
- Steinar Madsen, Medical Director, Norwegian Medicines Agency
- Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences

Proudly sponsored by Schwegman Lundberg & Woessner.
Platinum Media Partner – Biosimilar News. Supported by Drug Target Review.

For sponsorship inquiries, contact Alia Malick at +44 (0) 7827 6168 or email amalick@smi-online.co.uk

For media inquiries, contact Julia Rotar at +44 (0) 20 7827 6088 or email jrotar@smi-online.co.uk

To register, contact Fateja Begum at +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk

Biosimilars & Biobetters USA

Iselin, New Jersey

16th-17th November 2015

<http://www.biosimilars-usa.com/einnews>

*Markets and Markets report. Nov. 18, 2013 <http://goo.gl/nxHzDP>

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Fateja Begum

SMi Group Ltd

+44 (0) 20 7827 6184

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist

you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2017 IPD Group, Inc. All Right Reserved.